Doqualast is an antiasthmatic and antiallergic agent. It has a mode of antiallergic action similar to that of disodium cromoglycate and inhibits antigen-induced mediator release by interfering with the calcium transport required for histamine secretion across the mast cell membrane. In rabbits, no embryotoxic or teratogenic effects of doqualast were observed. The concomitant use of doqualast and theophylline might cause drug interaction. Doqualast is thought to increase the blood free fraction of concomitantly used theophylline and to accelerate elimination of theophylline from blood.

Chlorphenesin is a preservative and cosmetic biocide that helps prevent the growth of microorganisms. In cosmetics and personal care products, Chlorphenesin is used in the formulation of aftershave lotions, bath products, cleansing products, deodorants, hair conditioners, makeup, skin care products, personal cleanliness products, and shampoos. Chlorphenesin has been reported to cause irritation and contact dermatitis in some people, particularly those with sensitive and dry skin. The Cosmetic Ingredient Review (CIR) expert panel released a safety assessment in October 2012, however, that stated chlorphenesin at 0.3 percent (as it exists in personal care products) was classified as having “negligible dermal irritation potential.”

Repirinast is an antiallergic drug developed and introduced into the market in Japan in 1987. It is a histamine release inhibitor. It has demonstrated effectiveness for treating bronchial asthma in humans.